cmAngio® vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
cmAngio® is designed for radiologists and OB/GYNs to identify breast arterial calcifications on mammograms as an indicator of cardiovascular risk. In contrast, EchoGo Amyloidosis is for cardiologists, analyzing echocardiogram video clips to aid in the early detection of cardiac amyloidosis. While both contribute to cardiovascular health insights through AI, they utilize different imaging modalities and target distinct clinical conditions, making them complementary rather than directly comparable.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
cmAngiou00ae by CureMetrix is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. Ultromics' EchoGou00ae Amyloidosis is an FDA-cleared AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. EchoGo Amyloidosis analyzes echocardiogram video clips, specifically a single apical four-chamber echocardiographic video clip.
cmAngiou00ae provides visualization of BAC location on a scorecard and enables BAC identification and reporting without additional radiation or procedures. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on AI-powered analysis of echocardiographic markers like ventricular volume, cardiac function, and myocardial movement.
cmAngiou00ae is categorized for Cardiology AI, OB/GYN AI, and Radiology & Imaging AI, and is relevant for Cardiology, Obstetrics & Gynecology, and Radiology specialties. EchoGo Amyloidosis is primarily categorized for Cardiology AI and is designed for Cardiology specialists.
EchoGo Amyloidosis reports high diagnostic accuracy with 85% sensitivity and 93% specificity, demonstrating consistent performance across CA subtypes (AL, wild-type ATTR, variant ATTR). cmAngiou00ae does not publicly list specific sensitivity or specificity metrics, but states it has an adjustable operating point to meet clinical goals and demonstrated performance across all breast densities.
cmAngiou00ae is compatible with any DICOM-compliant viewer and boasts quick and easy installation, typically less than an hour. EchoGo Amyloidosis offers seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, and requires no additional hardware or software installations.